Does Optilume drug-coated balloon dilation compromise female sphincter function?
International Urology and Nephrology · 2025
DOI: 10.1007/s11255-025-04513-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Urology and Nephrology, 2025. Verfasst von Lukas Andrius Jelisejevas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Medical University Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. lukas.jelisejevas@i-med.ac.at. Hauptthemen laut MEDLINE: Dilatation, Urethral Stricture, Urethra. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Innsbruck and Medical University of Innsbruck.
Abstract (Originalsprache)
Purpose
Female urethral strictures (FUS) are rare, yet when present very bothersome. Repeated dilation often results in recurrence, requiring surgical urethral reconstruction in the long term. We assessed the outcomes of female patients with urethral stricture disease undergoing Optilume drug-coated-balloon (DCB) dilation.
Methods
Between August 2021 and May 2024, 14 female patients with FUS underwent DCB dilation. Two transgender male-to-female patients were excluded. The diagnosis was confirmed by inability to pass a 14Fr catheter, translabial ultrasound or voiding cystourethrogram (VCUG). Exclusion criteria were urinary tract infection, neurological disease and previous urethroplasty. Written consent was obtained prior to intervention and included the option of urethroplasty. After hydrophilic urethral dilation, urethrocystoscopy was performed. DCB (5 cm) dilation was done to 30Fr at 10 bar for 10 min. General or local anaesthesia was used depending on patient’s preference. Transurethral catheter was placed for 2–5 days. Endpoints were urinary continence, anatomical success (≥ 14Fr by cystoscopy/calibration) and freedom from repeat intervention at 6 months.
Results
The mean age was 52.3 years (range: 31–81), the mean number of prior interventions was 4.3 (range: 0–40). The mean follow-up was 12 months (range: 6–41). At the time of analysis, 11 out of 12 subjects (91.7%) were free from recurrence and repeat intervention. All patients remained continent after the intervention, with two reporting complete resolution of preexisting incontinence. Limitations of the study include the small sample size, short follow-up and single centre nature.
Conclusions
Optilume DCB dilation demonstrates short-term efficacy, is well tolerated, safe, and notably preserves sphincter function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Medical University Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. lukas.jelisejevas@i-med.ac.at.
- Department of Urology, Medical University Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.
Förderung
- University of Innsbruck and Medical University of Innsbruck
Zitieren
APA
Jelisejevas, L. A., Tulchiner, G., Kink, P., & Rehder, P. (2025). Does Optilume drug-coated balloon dilation compromise female sphincter function?. International Urology and Nephrology. https://doi.org/10.1007/s11255-025-04513-2
Vancouver
Jelisejevas LA, Tulchiner G, Kink P, Rehder P. Does Optilume drug-coated balloon dilation compromise female sphincter function?. International Urology and Nephrology. 2025. doi:10.1007/s11255-025-04513-2
BibTeX
@article{Jelisejevas2025,
author = {Jelisejevas, Lukas Andrius and Tulchiner, Gennadi and Kink, Patricia and Rehder, Peter},
title = {Does Optilume drug-coated balloon dilation compromise female sphincter function?},
journal = {International Urology and Nephrology},
year = {2025},
doi = {10.1007/s11255-025-04513-2}
}
EUVIMED